Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04956107
Other study ID # Preserve
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 25, 2021
Est. completion date September 1, 2023

Study information

Verified date November 2022
Source University of Aarhus
Contact Rogini Balachandran, MD
Phone +4542400620
Email rogbal@rm.dk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to describe type and extent of psychological distress (adverse effects) in patients undergoing surgery for colorectal cancer with peritoneal metastases and after surgery for colorectal cancer with involvement of the urinary bladder.


Description:

After being informed about the study all patients giving written informed consent will be distributed a questionnaire asking questions on depression, anxiety, self-reported cognitive issues, sleep issues, quality of life and 'fear of cancer recurrence'. All these aspects will be investigated using validated questionnaires. Once the investigators have the preliminary results (type and extent of psychological distress developed after CRS+HIPEC or PE) the investigators plan to conduct a workshop. In this workshop experts in different areas regarding psychological distress, project leaders, professor from the 'National Center of Late Adverse Effects after Cancer in Pelvic Organs' (Denmark) and patients will participate. With the input of experts and patients, a treatment strategy will be developed, and also an assessment will be made concerning which patients are likely to benefit from treatment by these experts, and which patients could potentially benefit from counselling by their general practitioner or via self-helping tools at home. The investigators plan to conduct this workshop autumn 2021 and start counselling spring 2022.


Recruitment information / eligibility

Status Recruiting
Enrollment 225
Est. completion date September 1, 2023
Est. primary completion date September 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients who have undergone intended curative CRS+HIPEC for peritoneal metastases originated from colorectal cancer (HIPEC cohort) according to national Danish guidelines - Patients who have undergone intended curative total or anterior pelvic exenteration (PE cohort) for advanced or recurrent colorectal cancer according to national Danish guidelines Exclusion Criteria: - Patients under 18 years - Patients not speaking Danish or Swedish, respectively, in Denmark and Sweden - Patients unable to give informed consent - Patients undergoing CRS+HIPEC or PE for cancers others than CRC - Terminally ill patients

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Denmark Department of Surgery, Aarhus University Hospital Aarhus
Sweden Department of Surgery, Skånes University Hospital, Malmö Malmö
Sweden Department of Surgery, Karolinska University Hospital Solna Stockholm

Sponsors (3)

Lead Sponsor Collaborator
University of Aarhus Karolinska University Hospital, Skane University Hospital

Countries where clinical trial is conducted

Denmark,  Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Development of depression after PE or CRS+HIPEC for colorectal cancer Descriptive analysis will be done using the following questionnaire: PHQ-9 (patient health questionnaire) PE cohort: Development and change in adverse effects 3, 6 and 12 months after surgery. HIPEC cohort: Development and change in adverse effects 3, 6, 12, 18, 24, 36, 48 and 60 months after surgery
Primary Development of anxiety after PE or CRS+HIPEC for colorectal cancer Descriptive analysis will be done using the following questionnaire: GAD-7 (general anxiety disorder) PE cohort: Development and change in adverse effects 3, 6 and 12 months after surgery. HIPEC cohort: Development and change in adverse effects 3, 6, 12, 18, 24, 36, 48 and 60 months after surgery
Primary Development of cognitive dysfunction after PE or CRS+HIPEC for colorectal cancer Descriptive analysis will be done using following the questionnaire: Items regarding cognitive functioning from the EORTC item library PE cohort: Development and change in adverse effects 3, 6 and 12 months after surgery. HIPEC cohort: Development and change in adverse effects 3, 6, 12, 18, 24, 36, 48 and 60 months after surgery
Primary Development of sleeping issues after PE or CRS+HIPEC for colorectal cancer Descriptive analysis will be done using following the questionnaire: ISI (insomnia sleep index) PE cohort: Development and change in adverse effects 3, 6 and 12 months after surgery. HIPEC cohort: Development and change in adverse effects 3, 6, 12, 18, 24, 36, 48 and 60 months after surgery
Primary Development of fatigue after PE or CRS+HIPEC for colorectal cancer Descriptive analysis will be done using following the questionnaire: FACIT V4 (fatigue scale) PE cohort: Development and change in adverse effects 3, 6 and 12 months after surgery. HIPEC cohort: Development and change in adverse effects 3, 6, 12, 18, 24, 36, 48 and 60 months after surgery
Primary Development of ´fear of cancer recurrence' after PE or CRS+HIPEC for colorectal cancer Descriptive analysis will be done using following the questionnaire: Fear of cancer recurrence - SF PE cohort: Development and change in adverse effects 3, 6 and 12 months after surgery. HIPEC cohort: Development and change in adverse effects 3, 6, 12, 18, 24, 36, 48 and 60 months after surgery
Secondary Risk factors associated with developing psychological distress Univariate and multivariate regression analysis will be performed to identify potential risk PE cohort: Development and change in adverse effects 3, 6 and 12 months after surgery. HIPEC cohort: Development and change in adverse effects 3, 6, 12, 18, 24, 36, 48 and 60 months after surgery.
See also
  Status Clinical Trial Phase
Recruiting NCT05074966 - The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts Phase 3
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Suspended NCT05124743 - HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Recruiting NCT05056389 - Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA) Phase 1
Completed NCT04551001 - Evaluation of Cold Forcep and Cold Snare Polypectomy for Polyps Less Than or Equal to 3mm in Size During Colonoscopy N/A
Completed NCT04551014 - Evaluation of EverLift in the Performance of Polypectomy for Polyps 4-9mm N/A
Recruiting NCT04270500 - The Impact of Physical Exercise on Sleep in Colorectal Cancer Patients During Prehabilitation Period N/A
Recruiting NCT03667911 - Virtual Reality Videos in Improving Bowel Preparation Quality of Colonoscopy N/A
Not yet recruiting NCT04073680 - A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05572684 - A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors Phase 1/Phase 2
Suspended NCT04108481 - Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer Phase 1/Phase 2
Completed NCT03567850 - Problem Solving Skills Training in Adult Cancer Survivors: Bright IDEAS-AC N/A
Recruiting NCT05870332 - Nationwide Study of Artificial Intelligence in Adenoma Detection for Colonoscopy
Completed NCT04534218 - Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer Phase 2
Enrolling by invitation NCT05590117 - Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer Early Phase 1
Recruiting NCT03129139 - A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelideā„¢ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors Phase 1
Completed NCT04195646 - Computer Aided Detection of Polyps During Colonoscopy Procedures N/A
Not yet recruiting NCT03618329 - Effect of Prehabilitation on the Lean Mass Index (IMM) in ERAS PROGRAMM. N/A
Not yet recruiting NCT03261752 - New Genes in the Carcinogenesis of Colorectal Cancer
Terminated NCT03621982 - Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Phase 1